Cormorant Asset Management, LP
CIK 1583977 · last filed 2026-08-10
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
CRBP price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
50TH FLOOR
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| BlossomHill Therapeutics, Inc. (BLSM) Delisted | 10%+ Owner | 3,301,534 | $16.39 | $54.11M | $30.00M | 1 | 2026-08-10 |
| CRBP | 10%+ Owner | 2,344,971 | $3.99 | $9.36M | $68.95M | 2 | 2025-12-15 |
| GreenLight Biosciences Holdings, PBC (GRNAW) Delisted | 0 | $0.02 | $0 | $0 | 1 | 2023-07-24 | |
| BMEA | Director | 3,170,872 | $0.64 | $2.02M | $61.20M | 3 | 2022-06-24 |
| Ventyx Biosciences, Inc. (VTYX) Delisted | 1,410,303 | $13.99 | $19.73M | $40.00M | 1 | 2021-10-27 | |
| Icosavax, Inc. (ICVX) Delisted | 426,393 | $15.31 | $6.53M | $0 | 1 | 2021-08-04 | |
| ERAS | 10%+ Owner | 10,505,553 | $14.99 | $157.48M | $60.80M | 1 | 2021-07-22 |
| Jade Biosciences, Inc. (AVTE) Delisted | 58,020 | $93.80 | $5.44M | $28.00M | 1 | 2021-07-07 | |
| Elevation Oncology, Inc. (ELEV) Delisted | 2,233,168 | $0.36 | $815.1K | $16.00M | 1 | 2021-07-01 | |
| AVIR | 6,411,355 | $4.16 | $26.67M | $0 | 1 | 2020-11-05 | |
| Akouos, Inc. (AKUS) Delisted | 499,989 | $13.29 | $6.64M | $19.72M | 1 | 2020-07-02 | |
| Apellis Pharmaceuticals, Inc. (APLS) Delisted | 10%+ Owner | 2,402,497 | $41.03 | $98.57M | $60.00M | 1 | 2017-11-14 |
Recent Filings · Page 2 of 2
15 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-04-22 | BMEA | Mixed | +12,683,488 | $61.20M | EDGAR |
| 2021-04-19 | BMEA | Grant (A) | — | $0 | EDGAR |
| 2020-11-05 | AVIR | Conv (C) | +32,056,775 | $0 | EDGAR |
| 2020-07-02 | Akouos, Inc. (AKUS) Delisted | Mixed | +3,159,956 | $19.72M | EDGAR |
| 2017-11-14 | Apellis Pharmaceuticals, Inc. (APLS) Delisted | Mixed | +13,895,700 | $60.00M | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.